To view this email as a web page, go here.

To make sure you continue to receive this e-newsletter, please add memberservices@IPNonline.com to your address book.

 
                                                          About Us Contact Us  
 
 
 

Confidence From In-office Administration

STELARA® (ustekinumab) Is Available as a Single-dose, 45 mg Vial

 

The single-dose vial for subcutaneous (subQ) injection will benefit your patients and practice with in-office administration and physician pricing.

A discount program is available for physician practices. For more information, consult your Janssen sales representative or call the Contract Hotline at 1-866-317-2764 today!

 
 
 

STELARA® 4 JOINT SYMPTOM RELIEF IN BIOLOGIC-NAÏVE PATIENTS

ACR20 RESPONSE AMONG BIOLOGIC-NAÏVE PATIENTS THROUGH WEEK 24*

PRIMARY ENDPOINT (PSUMMIT I)

The primary endpoint at Week 24 saw 42% (87/205) of patients receiving STELARA® 45 mg achieve ACR20 response. Fifty percent (101/204) of patients taking STELARA® 90 mg also achieved ACR20 response vs 23% (47/206) of patients taking placebo (P<0.0001 vs placebo for each dose). Patients achieved ACR20 response rates after only 3 doses with consistent results through Week 100.1-3*

STELARA® 4 CONSISTENT ACR20 RESPONSE RATES IN BIOLOGIC-NAÏVE PATIENTS THROUGH WEEK 1002-4 †‡

 
 
  • The percentage of biologic-naïve patients receiving STELARA® who achieved significant improvement in joint symptoms peaked at Week 28 and remained consistent through Week 1002-4
  • Patients were randomized to receive STELARA® 45 mg, STELARA® 90 mg, or placebo as subQ injection at Weeks 0 and 4 and every 12 weeks thereafter. At Week 24, all remaining patients in the placebo group received STELARA® 45 mg, which they continued at Week 28 and every 12 weeks thereafter2-4
 

PERCENTAGE OF BIOLOGIC-NAÏVE PATIENTS WITH NO SIGNS OF RESIDUAL ENTHESITIS THROUGH WEEK 1002-4 †‡

 

PERCENTAGE OF BIOLOGIC-NAÏVE PATIENTS WITH NO SIGNS OF RESIDUAL DACTYLITIS THROUGH WEEK 100†‡

 

PERCENTAGE OF BIOLOGIC-NAÏVE PATIENTS WITH ≥3% INITIAL BSA ACHIEVING PASI 75 THROUGH WEEK 100†‡¶

 

AT WEEK 108, THE SAFETY PROFILE FOR STELARA® WAS CONSISTENT WITH RESULTS AT WEEK 523,4

 

*Previous exposure to anti-tumor necrosis factor (TNF) agents was not allowed. Two patients had prior exposure to biologics: 1 to alefacept and 1 to efalizumab.3

PSUMMIT I was considered an open-label trial after Week 24.

In this ITT analysis, early escape rules were not applied. Efficacy evaluations were based on the patients' initial randomized assignments. Patients who qualified for early escape from the 45-mg group (and therefore received a 90-mg dose starting at Week 16) were counted in the 45-mg group. Concomitant medications were required to remain at stable doses through Week 52.3

§At Week 24, all remaining patients in the placebo group, who did not qualify for early escape, crossed over to STELARA® 45 mg, which they continued at Week 28 and every 12 weeks thereafter.2,3

llPatients who did not receive a dose of STELARA® after crossing over to STELARA ® 45 mg from the placebo group were excluded from the enthesitis/dactylitis analysis.3

In patients with ≥3% body surface area (BSA) affected by psoriasis at baseline.

#Combined 45-mg group: includes those randomized to 45 mg and those who switched from 45 mg to 90 mg.3

**1 of these was from the placebo crossover to 45-mg group.3

 

INDICATIONS

STELARA® (ustekinumab) is indicated for the treatment of adult patients with active psoriatic arthritis. STELARA® can be used alone or in combination with methotrexate (MTX).

STELARA® IN ACTIVE PsA1

  • The recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks
  • For patients with coexistent moderate to severe plaque psoriasis weighing >220 lbs, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks

STELARA® , available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up visits with a physician. If a physician determines that it is appropriate, a patient may self-inject or a caregiver may inject STELARA® after proper training in subcutaneous injection technique. Patients should be instructed to follow the directions provided in the Medication Guide.

 

Important Safety Information

Infections

STELARA® (ustekinumab) may increase the risk of infections and reactivation of latent infections. Serious bacterial, fungal, and viral infections, some requiring hospitalization, were reported. In patients with psoriasis, serious infections included diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis and urinary tract infections. In patients with psoriatic arthritis, serious infections included cholecystitis. In patients with Crohn’s disease, serious or other clinically significant infections included anal abscess, gastroenteritis, ophthalmic herpes, pneumonia, and Listeria meningitis.

Treatment with STELARA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of STELARA ® in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with STELARA® and consider discontinuing STELARA® for serious or clinically significant infections until the infection resolves or is adequately treated.

Theoretical Risk for Vulnerability to Particular Infections

Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria, Salmonella, and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients. It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with STELARA ® may be susceptible to these types of infections. Appropriate diagnostic testing should be considered, e.g., tissue culture, stool culture, as dictated by clinical circumstances.

Pre-Treatment Evaluation of Tuberculosis (TB)

Evaluate patients for TB prior to initiating treatment with STELARA®. Do not administer STELARA® to patients with active tuberculosis infection. Initiate treatment of latent TB before administering STELARA®. Closely monitor patients receiving STELARA® for signs and symptoms of active TB during and after treatment.

Malignancies

STELARA® is an immunosuppressant and may increase the risk of malignancy. Malignancies were reported among patients who received STELARA® in clinical studies. The safety of STELARA ® has not been evaluated in patients who have a history of malignancy or who have a known malignancy.

There have been reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving STELARA® who had risk factors for developing nonā€melanoma skin cancer (NMSC). All patients receiving STELARA ®, especially those >60 years or those with a history of PUVA or prolonged immunosuppressant treatment, should be monitored for the appearance of NMSC.

Hypersensitivity Reactions

STELARA® is contraindicated in patients with clinically significant hypersensitivity to ustekinumab or excipients. Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with STELARA ®. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue STELARA®.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS)

One case of reversible posterior leukoencephalopathy syndrome (RPLS) was observed in clinical studies of psoriasis and psoriatic arthritis. No cases of RPLS were observed in clinical studies of Crohn’s disease. If RPLS is suspected, administer appropriate treatment and discontinue STELARA® . RPLS is a neurological disorder, which is not caused by an infection or demyelination. RPLS can present with headache, seizures, confusion, and visual disturbances. RPLS has been associated with fatal outcomes.

Immunizations

Prior to initiating therapy with STELARA®, patients should receive all age-appropriate immunizations recommended by current guidelines. Patients being treated with STELARA® should not receive live vaccines. BCG vaccines should not be given during treatment or within one year of initiating or discontinuing STELARA®. Exercise caution when administering live vaccines to household contacts of STELARA® patients, as shedding and subsequent transmission to STELARA® patients may occur. Non-live vaccinations received during a course of STELARA ® may not elicit an immune response sufficient to prevent disease.

Concomitant Therapies

The safety of STELARA® in combination with other immunosuppressive agents or phototherapy was not evaluated in clinical studies of psoriasis. Ultraviolet-induced skin cancers developed earlier and more frequently in mice. In psoriasis studies, the relevance of findings in mouse models for malignancy risk in humans is unknown. In psoriatic arthritis studies, concomitant MTX use did not appear to influence the safety or efficacy of STELARA® . In Crohn’s disease studies, concomitant use of 6-mercaptopurine, azathioprine, methotrexate and corticosteroids did not appear to influence the overall safety or efficacy of STELARA®.

Allergen Immunotherapy

STELARA® may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. Therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.

Most Common Adverse Reactions

The most common adverse reactions (≥3% and higher than that with placebo) in adults from psoriasis clinical studies for STELARA® 45 mg, STELARA® 90 mg, or placebo were: nasopharyngitis (8%, 7%, 8%), upper respiratory tract infection (5%, 4%, 5%), headache (5%, 5%, 3%), and fatigue (3%, 3%, 2%), respectively. The safety profile in adolescents with plaque psoriasis through Week 60 was similar to that of adults with plaque psoriasis. In psoriatic arthritis (PsA) studies, a higher incidence of arthralgia and nausea was observed in patients treated with STELARA® when compared with placebo (3% vs 1% for both). In Crohn’s disease induction studies, common adverse reactions (3% or more of patients treated with STELARA ® and higher than placebo) reported through Week 8 for STELARA® 6 mg/kg intravenous single infusion or placebo included: vomiting (4% vs 3%). In the Crohn’s disease maintenance study, common adverse reactions (3% or more of patients treated with STELARA® and higher than placebo) reported through Week 44 were: nasopharyngitis (11% vs 8%), injection site erythema (5% vs 0%), vulvovaginal candidiasis/mycotic infection (5% vs 1%), bronchitis (5% vs 3%), pruritus (4% vs 2%), urinary tract infection (4% vs 2%) and sinusitis (3% vs 2%).

Please see full Prescribing Information and Medication Guide for STELARA ® at STELARAhcp.com. Provide the Medication Guide to your patients and encourage discussion.

081646-171004

 

References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. McInnes IB, Kavanaugh A, Gottlieb AB, et al; for the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet. 2013;382(9894):780-789. 3. Data on file. Janssen Biotech, Inc. 4. Kavanaugh A, Puig L, Gottlieb AB, et al; on behalf of the PSUMMIT 1 Study Group. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken). 2015;67(12):1739-1749.

 

© Janssen Biotech, Inc. 2018   02/18   cp-50563v1

 

Content developed by

Stelara® Logo
This email was sent to: amy.gonsuron@iononline.com

This email was sent by: IPN
3101 Gaylord Pkwy Frisco, TX, 75034

We respect your right to privacy - view our policy

Update Profile or Unsubscribe From All Lists